The Goldman Sachs Group Begins Coverage on ImmunoGen (NASDAQ:IMGN)
The Goldman Sachs Group began coverage on shares of ImmunoGen (NASDAQ:IMGN – Free Report) in a research report released on Monday morning, Marketbeat reports. The brokerage issued a neutral rating and a $17.00 price target on the biotechnology company’s stock. Several other analysts have also recently weighed in on the company. BMO Capital Markets lifted […]
More Stories
Ultrapar Participações (NYSE:UGP) Shares Down 2.6% – Time to Sell?
Shares of Ultrapar Participações S.A. (NYSE:UGP – Get Free Report) were down 2.6% on Thursday . The stock traded as...
Ultrapar Participações (NYSE:UGP) Shares Down 2.6% – Time to Sell?
Shares of Ultrapar Participações S.A. (NYSE:UGP – Get Free Report) were down 2.6% on Thursday . The stock traded as...
Reddit (NYSE:RDDT) Hits New 12-Month High – Here’s Why
Reddit, Inc. (NYSE:RDDT – Get Free Report) shares reached a new 52-week high during mid-day trading on Thursday . The...
Reddit (NYSE:RDDT) Hits New 12-Month High – Here’s Why
Reddit, Inc. (NYSE:RDDT – Get Free Report) shares reached a new 52-week high during mid-day trading on Thursday . The...
Canadian Solar (NASDAQ:CSIQ) Trading Down 2.5% – Should You Sell?
Canadian Solar Inc. (NASDAQ:CSIQ – Get Free Report) shares were down 2.5% during mid-day trading on Thursday . The company...
Canadian Solar (NASDAQ:CSIQ) Trading Down 2.5% – Should You Sell?
Canadian Solar Inc. (NASDAQ:CSIQ – Get Free Report) shares were down 2.5% during mid-day trading on Thursday . The company...